

AGENDA

***Uniform Formulary Beneficiary Advisory Panel (BAP)
23 September 2020 @ 12:00 PM Eastern Daylight Time***

Virtual Meeting

- **Administrative Meeting starts at 11:30 AM Eastern Daylight Time**
- **Sign-In**
- **Roll Call**
- **Welcome and Opening Remarks**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended Tier 4/Not Covered candidates.

The P&T Committee made recommendations for the following drugs/drug classes during the August 2020 meeting:

- **Drug Class Reviews**
 - *Sleep Disorders: Wakefulness Promoting Agents Subclass*
 - *White Blood Cell Stimulants: Filgrastims and Pegfilgrastims*
 - *Psoriasis Agents*

- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
 - *apomorphine sublingual film (Kynmobi) – new formulation of apomorphine for Parkinson’s disease*
 - *bempedoic acid/ezetimibe (Nexlizet) – antilipidemic-1 fixed dose combination for atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH)*
 - *capmatinib (Tabrecta) – oncological agent for non-small cell lung cancer (NSCLC)*
 - *diclofenac epolamine 1.3% patch (Licart) – NSAID patch for acute pain*
 - *elagolix/estradiol/norethindrone (Oriahnn) – luteinizing hormone-releasing hormone agonists-antagonists for heavy bleeding with fibroids*
 - *fenfluramine (Fintepla) – anticonvulsant for Dravet syndrome*

- *halcinonide 0.1% topical solution (Halog) – high potency topical corticosteroid*
- *insulin lispro-aabc (Lyumjev) – another insulin lispro formulation for diabetes mellitus*
- *lactic acid; citric acid; potassium bitartrate vaginal gel (Phexxi) – miscellaneous contraceptive vaginal gel for on-demand contraception*
- *lemborexant (Dayvigo) – dual orexin receptor antagonist for insomnia*
- *leuprolide acetate injection (Fensolvi) – leuprolide formulation for central precocious puberty*
- *levonorgestrel/ethinyl estradiol transdermal system (Twirla) – Miscellaneous contraceptive*
- *minocycline 1.5% topical foam (Zilxi) – topical formulation of minocycline for rosacea*
- *nimodipine oral syringe (Nymalize) – new oral syringe formulation of nimodipine*
- *octreotide acetate injection (Bynfezia Pen) – new formulation of octreotide in a pre-filled pen*
- *osilodrostat (Isturisa) – miscellaneous endocrine agent for Cushing’s disease*
- *ozanimod (Zeposia) – Multiple Sclerosis agent*
- *pemigatinib (Pemazyre) – oncological agent for cholangiocarcinoma*
- *ripretinib (Qinlock) – oncological agent for gastrointestinal stromal tumors (GIST)*
- *selpercatinib (Retevmo) – oncological agent for NSCLC and thyroid cancer*
- *selumetinib (Koselugo) – oncological agent for Neurofibromatosis type 1*
- *tazarotene 0.045% lotion (Arazlo) – topical acne and rosacea agent*
- *tucatinib (Tukysa) – oncological agent for breast cancer*

➤ **Utilization Management Issues**

➤ ***Prior Authorization Criteria—New Manual PA Criteria***

- *Narcotic Analgesics and Combinations—tramadol 100 mg immediate release (IR) tablet*
- *Vitamins: Prenatal—prenatal multivitamin (Trinaz)*
- *Pulmonary-2 Agents: Long-Acting Beta Agonists (LABAs)—olodaterol (Striverdi Respimat)*
- *Gastrointestinal-2 Agents—teduglutide (Gattex)*

➤ ***Prior Authorization Criteria—Updated PA***

- *Gynecological Agents Miscellaneous—flibanserin (Addyi)*
- *Acne Agents: Isotretinoids— isotretinoin (Absorica, Absorica LD)*
- *Antibiotics: Tetracyclines—minocycline extended release (ER) (Solodyn, generics)*
- *Acne Agents: Topical Acne and Rosacea—dapson 5% and 7.5% gel (Aczone)*
- *Respiratory Interleukins—dupilumab injection (Dupixent)*
- *Pulmonary-1 Agents: Idiopathic Pulmonary Fibrosis (IPF)—nintedanib (Ofev)*
- *Oncologic Agents:*
 - *ovarian cancer: niraparib (Zejula), olaparib (Lynparza), and rucaparib (Rubraca)*
 - *melanoma: encorafenib (Braftovi)*
 - *multiple myeloma: selinexor (Xpovio)*
- *Targeted Immunomodulatory Biologics (TIBs)*
 - *adalimumab (Humira)*
 - *ustekinumab (Stelara)*
 - *ixekizumab (Taltz)*

- *secukinumab (Cosentyx)*

➤ **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.